Nuclear Medicine Techniques

  • Luca CerianiEmail author
  • Giorgio Treglia
  • Luca Giovanella


This chapter provides an introduction to nuclear medicine technique useful for evaluating head and neck endocrine diseases. Different radiotracers can be used for thyroid imaging and they can be classified in two groups: a) radiotracers describing the function of follicular cells and b) radiotracers mapping the proliferative activity of follicular cells. The first group includes technetium-99m-pertechnetate (99mTcO4–) and radioiodine; the second group includes Tc99m-methoxyisobutylisonitrile (99mTc-MIBI) and fluorodeoxyglucose (18F-FDG).

About parathyroid nuclear imaging, 99mTc-MIBI is the most used tracer in clinical practice, usually combined with a thyroid tracer. Planar and tomographic images can be used for detecting hyperfunctioning parathyroid glands. The role of PET tracers seems promising.

Lastly, several tracers evaluating different metabolic pathways can be used to detect neuroendocrine tumors of head and neck region.


Thyroid Parathyroid Neuroendocrine Scintigraphy SPECT PET 


  1. 1.
    Giovanella L (2009) Thyroid nodules: clinical management and differential diagnosis. Praxis 98:83–90CrossRefPubMedGoogle Scholar
  2. 2.
    Treglia G, Caldarella C, Saggiorato E et al (2013) Diagnostic performance of 99mTc-MIBI scan in predicting the malignancy of thyroid nodules: a meta-analysis. Endocrine 44:70–78CrossRefPubMedGoogle Scholar
  3. 3.
    Wonga KT, Choi FP, Lee YY et al (2008) Current role of radionuclide imaging in differentiated thyroid cancer. Cancer Imaging 8:159–162CrossRefGoogle Scholar
  4. 4.
    Baker CH, Morris JC (2004) The sodium-iodide symporter. Curr Drug Targets Immune Endocr Metabol Disord 4:167–174CrossRefPubMedGoogle Scholar
  5. 5.
    Giovanella L, Ceriani L, Treglia G (2014) Role of isotope scan, including positron emission tomography/computed tomography, in nodular goitre. Best Pract Res Clin Endocrinol Metab 28:507–518CrossRefPubMedGoogle Scholar
  6. 6.
    Moretti JL, Hauet N, Caglar M et al (2005) To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging 32:836–842CrossRefPubMedGoogle Scholar
  7. 7.
    Feine U, Lietzenmayer R, Hanke JP et al (1995) 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin 34:127–134PubMedGoogle Scholar
  8. 8.
    Grabellus F, Nagarajah L, Bockisch A et al (2012) Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 37:121–127CrossRefPubMedGoogle Scholar
  9. 9.
    Treglia G, Annunziata S, Muoio B et al (2013) The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview. Int J Endocrinol 2013:856189PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Thorens B (1993) Facilitated glucose transporters in epithelial cells. Annu Rev Physiol 55:591–608CrossRefPubMedGoogle Scholar
  11. 11.
    Schönberger J, Rüschoff J, Grimm D et al (2002) Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 12:747–754CrossRefPubMedGoogle Scholar
  12. 12.
    Hooft L, van der Veldt AA, van Diest PJ et al (2001) [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase I expression in the primary tumor. J Clin Endocrinol Metab 90:328–334CrossRefGoogle Scholar
  13. 13.
    Treglia G, Muoio B, Giovanella L et al (2013) The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol 270:1783–1787CrossRefPubMedGoogle Scholar
  14. 14.
    Hindiè E, Ugur O, Fuster D et al (2009) 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging 36:1201–1216CrossRefPubMedGoogle Scholar
  15. 15.
    Taieb D, Hindie E, Grassetto G et al (2012) Parathyroid scintigraphy: when, how, and why? A concise systematic review. Clin Nucl Med 37:568–574CrossRefPubMedGoogle Scholar
  16. 16.
    Fröberg AC, Valkema R, Bonjer HJ et al (2003) 99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy? Eur J Nucl Med Mol Imaging 30:193–196CrossRefPubMedGoogle Scholar
  17. 17.
    Cheung K, Wang TS, Farrokhyar F et al (2012) A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol 19:577–583CrossRefPubMedGoogle Scholar
  18. 18.
    Treglia G, Sadeghi R, Schalin-Jäntii C et al (2015) Detection rate of (99m) Tc-MIBI SPECT/CT in the preoperative planning of patients with primary hyperparathyroidism: a meta-analysis. Head Neck. doi: 10.1002/hed.24027 PubMedGoogle Scholar
  19. 19.
    Caldarella C, Treglia G, Isgrò MA et al (2013) Diagnostic performance of positron emission tomography using 11C-methionine in patients with suspected parathyroid adenoma: a meta-analysis. Endocrine 43:78–83CrossRefPubMedGoogle Scholar
  20. 20.
    Orevi M, Freedman N, Mishani E et al (2014) Localization of parathyroid adenoma by 11C-choline PET/CT: preliminary results. Clin Nucl Med 39:1033–1038CrossRefPubMedGoogle Scholar
  21. 21.
    Taïeb D, Varoquaux A, Chen CC et al (2013) Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. Semin Nucl Med 43:462–473PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Shulkin BL, Ilias I, Sisson JC et al (2006) Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 1073:374–382CrossRefPubMedGoogle Scholar
  23. 23.
    Slavikova K, Montravers F, Treglia G et al (2013) What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma? Curr Radiopharm 6:96–105CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Luca Ceriani
    • 1
    Email author
  • Giorgio Treglia
    • 1
  • Luca Giovanella
    • 1
  1. 1.Department of Nuclear Medicine and PET/CT CenterOncology Institute of Southern SwitzerlandBellinzona and LuganoSwitzerland

Personalised recommendations